The potential of DNA modifications as biomarkers and therapeutic targets in oncology

References

• Costello JF, Plass C. Methylation matters. J Med Genet 2001;38(5):285-303
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome — biological and translational implications. Nat Rev Cancer 2011;11(10):726-34
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59
   PubMed Web of Science ®Google Scholar
• Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6(8):597-610
   PubMed Web of Science ®Google Scholar
• Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16(1):6-21
   PubMed Web of Science ®Google Scholar
• Razin A, Riggs AD. DNA methylation and gene function. Science 1980;210(4470):604-10
   PubMed Web of Science ®Google Scholar
• Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324(5929):930-5
   PubMed Web of Science ®Google Scholar
• He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333(6047):1303-7
   PubMed Web of Science ®Google Scholar
• Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011;333(6047):1300-3
   PubMed Web of Science ®Google Scholar
• Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol 2013;14(6):341-56
   PubMed Web of Science ®Google Scholar
• Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008;9(6):465-76
   PubMed Web of Science ®Google Scholar
• Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl):245-54
   PubMed Web of Science ®Google Scholar
• Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007;8(4):253-62
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7(1):21-33
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, West J, Beck S. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum Mol Genet 2013;22(R1):R7-R15
   PubMed Web of Science ®Google Scholar
• Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest 2014;124(1):24-9
   PubMed Web of Science ®Google Scholar
• Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7(4):536-40
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96(15):8681-6
   PubMed Web of Science ®Google Scholar
• Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol 2000;15:835-42
   PubMed Web of Science ®Google Scholar
• Bjornsson HT, Sigurdsson MI, Fallin MD, et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 2008;299:2877-83
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102(30):10604-9
   PubMed Web of Science ®Google Scholar
• Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 2009;5(8):e1000602
   PubMed Web of Science ®Google Scholar
• Maegawa S, Hinkal G, Kim HS, et al. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 2010;20(3):332-40
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368(22):2059-74
   PubMed Web of Science ®Google Scholar
• Talens RP, Christensen K, Putter H, et al. Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs. Aging Cell 2012;11(4):694-703
   PubMed Web of Science ®Google Scholar
• Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012;22(1):50-5
   PubMed Web of Science ®Google Scholar
• You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012;22(1):9-20
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007;16(Spec No 1):R50-9
   PubMed Web of Science ®Google Scholar
• Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012;13(10):679-92
   PubMed Web of Science ®Google Scholar
• Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003;4(6):351-8
   PubMed Web of Science ®Google Scholar
• Plass C, Pfister SM, Lindroth AM, et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013;14(11):765-80
   PubMed Web of Science ®Google Scholar
• Nestor CE, Ottaviano R, Reddington J, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res 2012;22(3):467-77
   PubMed Web of Science ®Google Scholar
• Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468(7325):839-43
   PubMed Web of Science ®Google Scholar
• Laird A, Thomson JP, Harrison DJ, Meehan RR. 5-hydroxymethylcytosine profiling as an indicator of cellular state. Epigenomics 2013;5(6):655-69
   PubMed Web of Science ®Google Scholar
• Ficz G, Branco MR, Seisenberger S, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011;473(7347):398-402
   PubMed Web of Science ®Google Scholar
• Ficz G, Gribben JG. Loss of 5-hydroxymethylcytosine in cancer: cause or consequence? Genomics 2014;104(5):352-7
   PubMed Web of Science ®Google Scholar
• Xu Y, Wu F, Tan L, et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011;42(4):451-64
   PubMed Web of Science ®Google Scholar
• Kinney SM, Chin HG, Vaisvila R, et al. Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes. J Biol Chem 2011;286(28):24685-93
   PubMed Web of Science ®Google Scholar
• Jin SG, Jiang Y, Qiu R, et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011;71(24):7360-5
   PubMed Web of Science ®Google Scholar
• Haffner MC, Chaux A, Meeker AK, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011;2(8):627-37
   PubMedGoogle Scholar
• Bhattacharyya S, Yu Y, Suzuki M, et al. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Res 2013;41(16):e157
   PubMed Web of Science ®Google Scholar
• Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150(6):1135-46
   PubMed Web of Science ®Google Scholar
• Shi H, Wang MX, Caldwell CW. CpG islands: their potential as biomarkers for cancer. Expert Rev Mol Diagn 2007;7(5):519-31
   PubMed Web of Science ®Google Scholar
• Olkhov-Mitsel E, Bapat B. Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers. Cancer Med 2012;1(2):237-60
   PubMed Web of Science ®Google Scholar
• Rivera CM, Ren B. Mapping human epigenomes. Cell 2013;155(1):39-55
   PubMed Web of Science ®Google Scholar
• Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 2011;6(6):692-702
   PubMed Web of Science ®Google Scholar
• Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006;16(3):383-93
   PubMed Web of Science ®Google Scholar
• Harris RA, Wang T, Coarfa C, et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol 2010;28(10):1097-105
   PubMed Web of Science ®Google Scholar
• Hirotsune S, Hatada I, Komatsubara H, et al. New approach for detection of amplification in cancer DNA using restriction landmark genomic scanning. Cancer Res 1992;52(13):3642-7
   PubMed Web of Science ®Google Scholar
• Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999;8(3):459-70
   PubMed Web of Science ®Google Scholar
• Gebhard C, Schwarzfischer L, Pham TH, et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 2006;66(12):6118-28
   PubMed Web of Science ®Google Scholar
• Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005;37(8):853-62
   PubMed Web of Science ®Google Scholar
• Meissner A, Gnirke A, Bell GW, et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res 2005;33(18):5868-77
   PubMed Web of Science ®Google Scholar
• Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462(7271):315-22
   PubMed Web of Science ®Google Scholar
• Adey A, Shendure J. Ultra-low-input, tagmentation-based whole-genome bisulfite sequencing. Genome Res 2012;22(6):1139-43
   PubMed Web of Science ®Google Scholar
• Tost J, Schatz P, Schuster M, et al. Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic Acids Res 2003;31(9):e50
   PubMed Web of Science ®Google Scholar
• Liu L, Kron KJ, Pethe VV, et al. Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011;129(10):2454-62
   PubMed Web of Science ®Google Scholar
• Rawson JB, Manno M, Mrkonjic M, et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis 2011;32(5):741-7
   PubMed Web of Science ®Google Scholar
• Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011;473(7347):394-7
   PubMed Web of Science ®Google Scholar
• Robertson AB, Dahl JA, Vagbø CB, et al. A novel method for the efficient and selective identification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 2011;39(8):e55
   PubMed Web of Science ®Google Scholar
• Song CX, Szulwach KE, Fu Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 2011;29(1):68-72
   PubMed Web of Science ®Google Scholar
• Williams K, Christensen J, Pedersen MT, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011;473(7347):343-8
   PubMed Web of Science ®Google Scholar
• Booth MJ, Branco MR, Ficz G, et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012;336(6083):934-7
   PubMed Web of Science ®Google Scholar
• Yu M, Hon GC, Szulwach KE, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 2012;149(6):1368-80
   PubMed Web of Science ®Google Scholar
• Mikeska T, Bock C, Do H, et al. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn 2012;12(5):473-87
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Mikeska T, Krypuy M, et al. Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 2008;36(7):e42
   PubMed Web of Science ®Google Scholar
• Mikeska T, Felsberg J, Hewitt CA, et al. Analysing DNA methylation using bisulphite pyrosequencing. Methods Mol Biol 2011;791:33-53
   PubMedGoogle Scholar
• Wojdacz TK, Dobrovic A. Methylationsensitive high resolution melting (MSHRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007;35(6):e41
   PubMed Web of Science ®Google Scholar
• Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009;27(9):858-63
   PubMed Web of Science ®Google Scholar
• Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3(4):253-66
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med 2010;10(2):123-32
   PubMed Web of Science ®Google Scholar
• Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61(8):3225-9
   PubMed Web of Science ®Google Scholar
• Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61(9):3573-7
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005;11(3):1219-25
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005;11(18):6505-11
   PubMed Web of Science ®Google Scholar
• Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010;10:600
   PubMed Web of Science ®Google Scholar
• Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011;6(10):1632-8
   PubMed Web of Science ®Google Scholar
• Ahmed H, Cappello F, Rodolico V, Vasta GR. Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2009;2(3):146-56
   PubMed Web of Science ®Google Scholar
• Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60(21):5941-5
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001;58(3):335-8
   PubMed Web of Science ®Google Scholar
• Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014;14(6):395-405
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102(45):16368-73
   PubMed Web of Science ®Google Scholar
• Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature. Clin Chim Acta 2010;411(21–22):1611-24
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11(6):426-37
   PubMed Web of Science ®Google Scholar
• Li L, Choi JY, Lee KM, et al. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol 2012;22(5):384-94
   PubMed Web of Science ®Google Scholar
• Maier S, Nimmrich I, Koenig T, et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – technical and clinical validation in a multi-centre setting in collaboration with the European organisation for research and treatment of cancer (EORTC) pathobiology group. Eur J Cancer 2007;43:1679-86
   PubMed Web of Science ®Google Scholar
• Strand SH, Orntoft TF, Sorensen KD. Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 2014;15(9):16544-76
   PubMed Web of Science ®Google Scholar
• Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28
   PubMed Web of Science ®Google Scholar
• Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers. Biomark Med 2013;7(1):49-58
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4
   PubMed Web of Science ®Google Scholar
• Fernandez AF, Assenov Y, Martin-Subero JI. et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2011;22(2):407-19
   PubMed Web of Science ®Google Scholar
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nature biotechnology 2010;28:1069-78
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29(15):1987-96
   PubMed Web of Science ®Google Scholar
• Hatzimichael E, Crook T. Cancer epigenetics: new therapies and new challenges. J Drug Deliv 2013;2013:529312
   PubMedGoogle Scholar
• Chung CW, Witherington J. Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J Biomol Screen 2011;16(10):1170-85
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468(7327):1067-73
   PubMed Web of Science ®Google Scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340(6132):626-30
   PubMed Web of Science ®Google Scholar